Feasibility and safety of hepatic artery infusion of G-CSF mobilized peripheral blood CD34+ haematopoietic stem cells in patients with cirrhosis: A pilot study

Background: At present, orthotopic liver transplantation is the only therapeutic option for patients with end-stage liver disease. However, due to shortage of the donor organs, 50% of patients die while on the waiting list. Hence, a search for alternative treatment modalities is essential. Adult ste...

Full description

Bibliographic Details
Main Authors: A Arora, P Ranjan, N Bansal, A Gupta, M Bhargava, A Saraf, R K Saran, P Tyagi, P Sharma, S K Sama, A Kumar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Current Medicine Research and Practice
Subjects:
Online Access:http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2013;volume=3;issue=1;spage=5;epage=17;aulast=Arora
_version_ 1811313891760668672
author A Arora
P Ranjan
N Bansal
A Gupta
M Bhargava
A Saraf
R K Saran
P Tyagi
P Sharma
S K Sama
A Kumar
author_facet A Arora
P Ranjan
N Bansal
A Gupta
M Bhargava
A Saraf
R K Saran
P Tyagi
P Sharma
S K Sama
A Kumar
author_sort A Arora
collection DOAJ
description Background: At present, orthotopic liver transplantation is the only therapeutic option for patients with end-stage liver disease. However, due to shortage of the donor organs, 50% of patients die while on the waiting list. Hence, a search for alternative treatment modalities is essential. Adult stem cell-based treatment is evolving as a viable clinical alternative. We conducted a pilot study to assess the feasibility and safety of hepatic artery (HA) infusion of granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood CD34+ haematopoietic stem cells (HSCs) in patients with cirrhosis of the liver. Patients and methods: Consecutive patients of cirrhosis were treated with 5 days of G-CSF stimulation for mobilization of peripheral blood HSCs (CD34+ cells). Patients who achieved a minimum CD34+ cell count of >10/mcL after G-CSF stimulation underwent apheresis. The cell suspension thus obtained after apheresis was then infused into the HA of these patients. The patients who failed to achieve the desired CD34+ cell count of >10/mcL did not undergo HA infusion. Patients of both the groups were followed up for 6 months for clinical and biochemical improvement in liver function, if any. Results: Of the 106 eligible patients, 12 patients (median age 53 years [range 44–63], 75% males) were included in the study. The median Child–Turcotte–Pugh (CTP) score was 10 (range 8–12) and the median Model for End-stage Liver Disease (MELD) score was 16 (range 10–23). All patients successfully completed the 5-day course of G-CSF stimulation without any adverse reactions. Eight of twelve (67%) patients could achieve the primary objective of the study (CD34+ cell count of >10/mcL). Six of these patients underwent apheresis and subsequent HA infusion of CD34+ cells, without any complications. There was significant improvement in the median CTP score in the HA infusion group which decreased by two points from the baseline. The CTP scores remained same in the G-CSF alone group. Similarly, there was improvement in the MELD scores in the HA infusion group at 6 months, while they remained same in the G-CSF alone group. Conclusions: HA infusion of G-CSF stimulated autologous CD34+ cells significantly improved the CTP and MELD scores which was maintained for 6 months. Five-day G-CSF stimulation is able to stimulate the bone marrow-derived CD34+ stem cells in about 67% cirrhotic patients. G-CSF stimulation, apheresis and HA infusion are safe procedures without any significant side-effects in cirrhotics. Thus, these procedures can be used as a safe bridge to transplantation in patients with decompensated cirrhosis.
first_indexed 2024-04-13T11:02:40Z
format Article
id doaj.art-cd6d055cb75f43a1928cba4ef1352809
institution Directory Open Access Journal
issn 2352-0817
2352-0825
language English
last_indexed 2024-04-13T11:02:40Z
publishDate 2013-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Current Medicine Research and Practice
spelling doaj.art-cd6d055cb75f43a1928cba4ef13528092022-12-22T02:49:23ZengWolters Kluwer Medknow PublicationsCurrent Medicine Research and Practice2352-08172352-08252013-01-0131517Feasibility and safety of hepatic artery infusion of G-CSF mobilized peripheral blood CD34+ haematopoietic stem cells in patients with cirrhosis: A pilot studyA AroraP RanjanN BansalA GuptaM BhargavaA SarafR K SaranP TyagiP SharmaS K SamaA KumarBackground: At present, orthotopic liver transplantation is the only therapeutic option for patients with end-stage liver disease. However, due to shortage of the donor organs, 50% of patients die while on the waiting list. Hence, a search for alternative treatment modalities is essential. Adult stem cell-based treatment is evolving as a viable clinical alternative. We conducted a pilot study to assess the feasibility and safety of hepatic artery (HA) infusion of granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood CD34+ haematopoietic stem cells (HSCs) in patients with cirrhosis of the liver. Patients and methods: Consecutive patients of cirrhosis were treated with 5 days of G-CSF stimulation for mobilization of peripheral blood HSCs (CD34+ cells). Patients who achieved a minimum CD34+ cell count of >10/mcL after G-CSF stimulation underwent apheresis. The cell suspension thus obtained after apheresis was then infused into the HA of these patients. The patients who failed to achieve the desired CD34+ cell count of >10/mcL did not undergo HA infusion. Patients of both the groups were followed up for 6 months for clinical and biochemical improvement in liver function, if any. Results: Of the 106 eligible patients, 12 patients (median age 53 years [range 44–63], 75% males) were included in the study. The median Child–Turcotte–Pugh (CTP) score was 10 (range 8–12) and the median Model for End-stage Liver Disease (MELD) score was 16 (range 10–23). All patients successfully completed the 5-day course of G-CSF stimulation without any adverse reactions. Eight of twelve (67%) patients could achieve the primary objective of the study (CD34+ cell count of >10/mcL). Six of these patients underwent apheresis and subsequent HA infusion of CD34+ cells, without any complications. There was significant improvement in the median CTP score in the HA infusion group which decreased by two points from the baseline. The CTP scores remained same in the G-CSF alone group. Similarly, there was improvement in the MELD scores in the HA infusion group at 6 months, while they remained same in the G-CSF alone group. Conclusions: HA infusion of G-CSF stimulated autologous CD34+ cells significantly improved the CTP and MELD scores which was maintained for 6 months. Five-day G-CSF stimulation is able to stimulate the bone marrow-derived CD34+ stem cells in about 67% cirrhotic patients. G-CSF stimulation, apheresis and HA infusion are safe procedures without any significant side-effects in cirrhotics. Thus, these procedures can be used as a safe bridge to transplantation in patients with decompensated cirrhosis.http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2013;volume=3;issue=1;spage=5;epage=17;aulast=Arorastem cellscirrhosiscd34+cd133+end-stage liver diseasechild–turcotte–pugh (cpt) score
spellingShingle A Arora
P Ranjan
N Bansal
A Gupta
M Bhargava
A Saraf
R K Saran
P Tyagi
P Sharma
S K Sama
A Kumar
Feasibility and safety of hepatic artery infusion of G-CSF mobilized peripheral blood CD34+ haematopoietic stem cells in patients with cirrhosis: A pilot study
Current Medicine Research and Practice
stem cells
cirrhosis
cd34+
cd133+
end-stage liver disease
child–turcotte–pugh (cpt) score
title Feasibility and safety of hepatic artery infusion of G-CSF mobilized peripheral blood CD34+ haematopoietic stem cells in patients with cirrhosis: A pilot study
title_full Feasibility and safety of hepatic artery infusion of G-CSF mobilized peripheral blood CD34+ haematopoietic stem cells in patients with cirrhosis: A pilot study
title_fullStr Feasibility and safety of hepatic artery infusion of G-CSF mobilized peripheral blood CD34+ haematopoietic stem cells in patients with cirrhosis: A pilot study
title_full_unstemmed Feasibility and safety of hepatic artery infusion of G-CSF mobilized peripheral blood CD34+ haematopoietic stem cells in patients with cirrhosis: A pilot study
title_short Feasibility and safety of hepatic artery infusion of G-CSF mobilized peripheral blood CD34+ haematopoietic stem cells in patients with cirrhosis: A pilot study
title_sort feasibility and safety of hepatic artery infusion of g csf mobilized peripheral blood cd34 haematopoietic stem cells in patients with cirrhosis a pilot study
topic stem cells
cirrhosis
cd34+
cd133+
end-stage liver disease
child–turcotte–pugh (cpt) score
url http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2013;volume=3;issue=1;spage=5;epage=17;aulast=Arora
work_keys_str_mv AT aarora feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy
AT pranjan feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy
AT nbansal feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy
AT agupta feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy
AT mbhargava feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy
AT asaraf feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy
AT rksaran feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy
AT ptyagi feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy
AT psharma feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy
AT sksama feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy
AT akumar feasibilityandsafetyofhepaticarteryinfusionofgcsfmobilizedperipheralbloodcd34haematopoieticstemcellsinpatientswithcirrhosisapilotstudy